HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
HLS Therapeutics Inc hisse başına yıllık % {var1} temettüye sahiptir ve % {var2} oranında bir getiri sunmaktadır. Temettü üç ayda bir ödenmektedir ve son temettü hariç tarihi Apr 27, 2023 tarihindedir.
Dividend Yield
Yıllık Dividende
Özsermaye Tarihi
0.00%
$0.00
Apr 27, 2023
Ödeme Sıklığı
Ödeme Oranı
Üç ayda bir
0.00%
Dividend History
Özsermaye Tarihi
Nakit Tutarı
Kayıt Tarihi
Ödeme Tarihi
Apr 27, 2023
$0.05
Apr 28, 2023
Jun 15, 2023
Jan 30, 2023
$0.05
Jan 31, 2023
Mar 15, 2023
Oct 28, 2022
$0.05
Oct 31, 2022
Dec 15, 2022
Jul 28, 2022
$0.05
Jul 29, 2022
Sep 15, 2022
Apr 28, 2022
$0.05
Apr 29, 2022
Jun 15, 2022
Jan 27, 2022
$0.05
Jan 28, 2022
Mar 15, 2022
Dividend Grafikleri
HLTRF Kâr Payları
HLTRF Dividend Growth (Yıllık Üstünlük)
Follow-Up Questions
HLS Therapeutics Inc'in şu anki temettü ödemesi ve yıllık temettüsü nedir?
HLS Therapeutics Inc'in temettü ödeme oranı nedir?